CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.


BACKGROUND:Approximately one third of Diffuse Large B cell Lymphomas (DLBCL) are refractory or relapse. Novel therapeutic approaches under scrutiny include inhibitors of B-cell receptor (BCR) signaling. Protein kinase CK2 propels survival, proliferation and stress response in solid and hematologic malignancies and promotes a "non-oncogene addiction" phenotype. Whether this kinase regulates BCR signaling, being a suitable pharmacological target in DLBCL, is unknown. OBJECTIVE:The objective was to establish if CK2 controls DLBCL cell survival and the BCR signaling, to check if the combination of CK2 inhibitor CX-4945 and BCR blockers Ibrutinib and Fostamatinib is more effectively cytotoxic for DLBCL cells than the single agents and to survey the changes in signaling molecules downstream BCR upon CK2 inhibition. METHOD:A panel of GC and ABC DLBCL cells was treated with CX-4945 and Fostamatinib or Ibrutinib. BCR signaling was assayed by intracellular Ca++ measurement and looking at the phosphorylation of signaling molecules. The effects on cell survival were assessed by flow cytometry, western blot and MTT assays. RESULTS:CK2 inhibition with CX-4945 causes DLBCL cell death. CX-4945 impaired AKT phosphorylation and intracellular Ca++ mobilization upon BCR engagement. The CK2 inhibitor acted synergistically with either the SYK inhibitor Fostamatinib or the BTK inhibitor Ibrutinib in inducing DLBCL cell death. CX-4945 was equally effective in GC and ABC DLBCL subtypes as well as in "double hit" DLBCL cell lines. CONCLUSION:These findings suggest a role for CK2 downstream of the BCR in controlling survival pathways crucial for cell growth of different DLBCL subtypes. Also, the use of CX-4945 in combination with BCR signaling blockers could represent a novel rational therapeutic approach in the DLBCL.


Mandato E,Nunes SC,Zaffino F,Casellato A,Macaccaro P,Tubi LQ,Visentin A,Trentin L,Semenzato G,Piazza F




Has Abstract


2018-01-01 00:00:00














  • Cetuximab: from bench to bedside.

    abstract::Cetuximab (IMC-C225, Erbitux ImClone Systems Inc, New York, NY) is a recombinant, human/mouse chimeric monoclonal antibody (MAb) that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR) on both normal and tumor cells, and competitively inhibits the binding of epidermal g...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审


    authors: Vincenzi B,Zoccoli A,Pantano F,Venditti O,Galluzzo S

    更新日期:2010-02-01 00:00:00

  • Transcription factors: molecular targets for prostate cancer intervention by phytochemicals.

    abstract::With increasing incidence of cancer at most of the sites, and growing economic burden and associated psychological and emotional trauma, it is becoming clearer that more efforts are needed for cancer cure. Since most of the chemotherapeutic drugs are non-selective because they are also toxic to the normal cells, new a...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审


    authors: Kaur M,Agarwal R

    更新日期:2007-06-01 00:00:00

  • Targeting Signaling Pathways in Chronic Lymphocytic Leukemia.

    abstract::Various signal transduction pathways have been implicated in the pathogenesis of chronic lymphocytic leukemia (CLL), which is characterized by the progressive accumulation of monoclonal CD5+ B cells in the blood. B cell receptor (BCR) signaling appears to have a crucial role in disease onset and is thought to be induc...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审


    authors: Muggen AF,Singh SP,Hendriks RW,Langerak AW

    更新日期:2016-01-01 00:00:00

  • Voltage-dependent potassium channels Kv1.3 and Kv1.5 in human cancer.

    abstract::Membrane ion channels participate in cancerous processes such as proliferation, migration and invasion, which contribute to metastasis. Increasing evidence indicates that voltage-dependent K(+) (Kv) channels are involved in the proliferation of many types of cells, including tumor cells. Kv channels have generated imm...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章


    authors: Bielanska J,Hernández-Losa J,Pérez-Verdaguer M,Moline T,Somoza R,Ramón Y Cajal S,Condom E,Ferreres JC,Felipe A

    更新日期:2009-12-01 00:00:00

  • Function and antagonism of beta3 integrins in the development of cancer therapy.

    abstract::The integrin family of cell surface receptors integrates cell-extracellular matrix interactions with the cell cytoskeleton and signalling across the cell membrane, resulting in an important role in cell adhesion, mobility and migration, proliferation, and survival. Changes in the number and identity of integrin recept...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审


    authors: Sheldrake HM,Patterson LH

    更新日期:2009-06-01 00:00:00

  • Pharmacogenomics opportunities in nuclear receptor targeted cancer therapy.

    abstract::Nuclear Hormone Receptors (NR) represent one of the most promising protein families in terms of therapeutic applications. These transcription factors are naturally switched on and off by small molecule hormones presenting physico-chemical properties very similar to therapeutic chemical entities. NRs represent therefor...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审


    authors: Schapira M

    更新日期:2002-09-01 00:00:00

  • Obesity-enhanced colon cancer: functional food compounds and their mechanisms of action.

    abstract::Obesity is rapidly becoming a global phenomenon. This is more than a cosmetic issue as obesity is associated with several life-threatening diseases, including colon cancer. Insulin resistance and inflammation, underlying factors in obesity-related diseases, promote colonocyte proliferation and suppress programmed cell...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审


    authors: Vanamala J,Tarver CC,Murano PS

    更新日期:2008-11-01 00:00:00

  • Formulation, Pharmacokinetic Evaluation and Cytotoxicity of an Enhanced- penetration Paclitaxel Nanosuspension.

    abstract:BACKGROUND:Improving poorly soluble drugs into druggability was a major problem faced by pharmaceutists. Nanosuspension can improve the druggability of insoluble drugs by improving the solubility, chemical stability and reducing the use of additives, which provided a new approach for the development and application of ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章


    authors: Cao Y,Wei Z,Li M,Wang H,Yin L,Chen D,Wang Y,Chen Y,Yuan Q,Pu X,Zong L,Duan S

    更新日期:2019-01-01 00:00:00

  • Black currant anthocyanins abrogate oxidative stress through Nrf2- mediated antioxidant mechanisms in a rat model of hepatocellular carcinoma.

    abstract::Hepatocellular carcinoma (HCC), considered to be one of the most lethal cancers with almost > 1 million deaths reported annually worldwide, remains a devastating disease with no known effective cure. Hence, chemopreventive strategies come into play, offering an effective and safe mode of treatment, ideal to ward off p...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章


    authors: Thoppil RJ,Bhatia D,Barnes KF,Haznagy-Radnai E,Hohmann J,Darvesh AS,Bishayee A

    更新日期:2012-11-01 00:00:00

  • Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer.

    abstract::The treatment of advanced non � small cell lung cancer (NSCLC) increasingly involves the use of molecularly targeted therapy with activity against either the tumor directly, or indirectly, through activity against host-derived mechanisms of tumor support such as angiogenesis. The most well studied signaling pathway as...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审


    authors: Kono SA,Heasley LE,Doebele RC,Camidge DR

    更新日期:2012-02-01 00:00:00

  • Phytochemicals for breast cancer therapy: current status and future implications.

    abstract::Breast cancer is one of the most common malignancies among women, representing nearly 30% of newly diagnosed cancers every year. Till date, various therapeutic interventions, including surgery, chemotherapy, hormonal therapy, and radiotherapy are available and are known to cause a significant decline in the overall mo...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审


    authors: Siddiqui JA,Singh A,Chagtoo M,Singh N,Godbole MM,Chakravarti B

    更新日期:2015-01-01 00:00:00

  • Elaborating the Role of Natural Products on the Regulation of Autophagy and their Potentials in Breast Cancer Therapy.

    abstract::Autophagy is an intracellular lysosomal/vacuolar degradation system, in which the inner cytoplasmic cell membrane is degraded by the lysosomal hydrolases, followed by the resulting products released back into the cytosol. It is involved in many physiological processes which are crucial for cell growth and survival. Ho...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审


    authors: Zhou X,Yue GG,Tsui SK,Pu J,Fung KP,Lau CB

    更新日期:2018-01-01 00:00:00

  • Arsenic trioxide exerts anti-lung cancer activity by inhibiting angiogenesis.

    abstract::Arsenic trioxide (As2O3) has been used in the clinic for the treatment of acute promyelocytic 1eukemia and some solid tumors. However, its effectiveness against lung cancer has not been well demonstrated, and the underlying mechanism(s) of action remain unclear. In the present study, we found that As2O3 significantly ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章


    authors: Yang MH,Zang YS,Huang H,Chen K,Li B,Sun GY,Zhao XW

    更新日期:2014-01-01 00:00:00

  • TXNL1 induces apoptosis in cisplatin resistant human gastric cancer cell lines.

    abstract::Cisplatin is one of the most commonly used drugs in the treatment of gastric cancer. However, drug resistance is a major obstacle for effective treatment and originates in multiple mechanisms such as enhanced DNA repair and anti-apoptosis. Our previous results demonstrated that XRCC1 was a key regulator of cisplatin i...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章


    authors: Ni P,Xu W,Zhang Y,Chen Q,Li A,Wang S,Xu S,Zhou J

    更新日期:2015-01-01 00:00:00

  • Design of new drug molecules to be used in reversing multidrug resistance in cancer cells.

    abstract::Over the past two decades, a number of chemical entities have been investigated in the continuing quest to reverse P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in cancer cells and some have undergone clinical trials, but currently none are in clinical use. Unfortunately, most of these agents suffer clinic...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审


    authors: Mayur YC,Peters GJ,Prasad VV,Lemo C,Sathish NK

    更新日期:2009-05-01 00:00:00

  • The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide.

    abstract::The total expression profiles of two medulloblastoma cell lines resistant to the preactivated form of cyclophosphamide (4-hydroperoxycyclophosphamide, 4-HC) were examined using the Affymetrix GeneChip U133A array. Our primary objective was to look for possible genes, other than the well-studied aldehyde dehydrogenases...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章


    authors: Bacolod MD,Lin SM,Johnson SP,Bullock NS,Colvin M,Bigner DD,Friedman HS

    更新日期:2008-05-01 00:00:00

  • Cell-penetrating Peptides for Cancer-targeting Therapy and Imaging.

    abstract::Cell-penetrating peptides (CPPs) have been previously shown to be powerful transport vector tools for the delivery of a large variety of cargoes through the cell membrane, as well as other physiological membranes. And since they're relatively cell-, receptor- and energy-independent, CPPs have unique advantages in faci...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审


    authors: Wang W,Abbad S,Zhang Z,Wang S,Zhou J,Lv H

    更新日期:2015-01-01 00:00:00

  • Role of Glioma-associated GLI1 Oncogene in Carcinogenesis and Cancertargeted Therapy.

    abstract::Glioma-associated oncogenes (GLIs) are zinc finger protein family members and downstream regulatory factors of the classic Hedgehog (Hh) signaling pathway. GLI proteins influence the growth and development of organisms and aid in tissue repair. However, aberrant expression of the GLI family member GLI1 promotes carcin...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审


    authors: Wu J,Di D,Zhao C,Liu Y,Chen H,Gong Y,Zhao X,Chen H

    更新日期:2018-01-01 00:00:00

  • Silica nanoparticles as promising drug/gene delivery carriers and fluorescent nano-probes: recent advances.

    abstract::The application of nanotechnology to biomedical research is expected to have a major impact leading to the development of new types of diagnostic and therapeutic tools. One focus in nanobiotechnology is to develop safe and efficient drug/gene delivery vehicles. Research into the rational delivery and targeting of phar...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审


    authors: Liu Y,Lou C,Yang H,Shi M,Miyoshi H

    更新日期:2011-02-01 00:00:00

  • Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics?

    abstract::Cancer is a disease in which cellular growth regulatory networks are disrupted. Lesions in well-characterized oncogenes and tumor suppressors often contribute to the dysregulation, but recent work has also uncovered the fundamental importance of enzymes that modulate the acetylation status of chromatin to the initiati...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审


    authors: Chen JS,Faller DV,Spanjaard RA

    更新日期:2003-06-01 00:00:00

  • Alternative splicing in chronic myeloid leukemia (CML): a novel therapeutic target?

    abstract::Although the imatinib based therapy of chronic myeloid leukemia (CML) represents a triumph of medicine, not all patients with CML benefit from this drug due to the development of resistance and intolerance. The interruption of imatinib treatment is often followed by clinical relapse, suggesting a failure in the killin...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审


    authors: Adamia S,Pilarski PM,Bar-Natan M,Stone RM,Griffin JD

    更新日期:2013-09-01 00:00:00

  • Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer.

    abstract::CXCR4 is a chemokine receptor implicated in the metastatic process. The CXCR4 ligand, CXCL12, was shown to bind also the CXCR7 receptor, a recently deorphanized chemokine receptor whose signalling pathway and function are still controversial. This study was conducted to determine patients clinic-pathological factors a...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章


    authors: D'Alterio C,Consales C,Polimeno M,Franco R,Cindolo L,Portella L,Cioffi M,Calemma R,Marra L,Claudio L,Perdonà S,Pignata S,Facchini G,Cartenì G,Longo N,Pucci L,Ottaiano A,Costantini S,Castello G,Scala S

    更新日期:2010-11-01 00:00:00

  • Macrophage Flipping from Foe to Friend: A Matter of Interest in Breast Carcinoma Heterogeneity Driving Drug Resistance.

    abstract::Tumor heterogeneity within various cancer types including breast carcinoma is pivotal in the manifestations of tumor hallmarks. Tumor heterogeneity is seen as a common landscape where intra-tumoral components including cellular and non-cellular factors create an interface with outside environment that leads to the uni...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审


    authors: Tandon I,Sharma NK

    更新日期:2019-01-01 00:00:00

  • Cathepsin D as a Promising Target for the Discovery of Novel Anticancer Agents.

    abstract:BACKGROUND:Cathepsin D (CATD), one of the aspartyl endoproteinase involved in different physiological processes and signaling pathways, is accountable for metabolic breakdown of intracellular proteins, the activation of growth factors, hormones, and precursors of enzyme, the processing of antigens, enzyme inhibitors an...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审


    authors: Dubey V,Luqman S

    更新日期:2017-01-01 00:00:00

  • Matrix metalloproteinases as therapeutic targets in cancer.

    abstract::Degradation of extracellular matrix is crucial for malignant tumor growth, invasion, metastasis and angiogenesis. Matrix metalloproteinases (MMPs) are a family of zinc-dependent neutral endopeptidases collectively capable of degrading essentially all matrix components. Elevated levels of distinct MMPs can be detected ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审


    authors: Vihinen P,Ala-aho R,Kähäri VM

    更新日期:2005-05-01 00:00:00

  • Gene Therapy and Photothermal Therapy of Layer-by-Layer Assembled AuNCs /PEI/miRNA/ HA Nanocomplexes.

    abstract:BACKGROUND:MicroRNA (miRNA) therapy, which was widely considered to treat a series of cancer, has been confronted with numerous obstacles to being delivered into target cells because of its easy biodegradation and instability. METHODS:In this research, we successfully constructed 11-mercaptoundecanoic acid modified go...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章


    authors: Yan LJ,Guo XH,Wang WP,Hu YR,Duan SF,Liu Y,Sun Z,Huang SN,Li HL

    更新日期:2019-01-01 00:00:00

  • Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia.

    abstract::Heat shock proteins (HSPs) are molecular chaperones that stabilize folding and conformation of normal as well as oncogenic proteins. These chaperones thereby prevent the formation of protein aggregates. HSPs are often overexpressed in human malignancies, including AML. HSP90 is the main chaperon required for the stabi...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审


    authors: Reikvam H,Ersvaer E,Bruserud O

    更新日期:2009-09-01 00:00:00

  • A cross-talk between NFAT and NF-κB pathways is crucial for nickel-induced COX-2 expression in Beas-2B cells.

    abstract::Cyclooxygenase-2 (COX-2) is a critical enzyme implicated in chronic inflammation-associated cancer development. Our studies have shown that the exposure of Beas-2B cells, a human bronchial epithelial cell line, to lung carcinogenic nickel compounds results in increased COX-2 expression. However, the signaling pathways...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章


    authors: Cai T,Li X,Ding J,Luo W,Li J,Huang C

    更新日期:2011-06-01 00:00:00

  • Antiandrogens in prostate cancer endocrine therapy.

    abstract::Prostate cancer is the most frequently diagnosed tumor in industrialized countries. Endocrine therapy, which is based on interference with androgen signaling is only palliative. Drugs used in prostate cancer therapy are luteinizing hormone releasing hormone (LHRH) agonists and antiandrogens. Application of LHRH agonis...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审


    authors: Culig Z,Bartsch G,Hobisch A

    更新日期:2004-08-01 00:00:00

  • Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.

    abstract::Targeted therapies focus on signaling pathways in cancer cells and other molecular processes involved in oncogenesis. Recent approaches affect the following major groups: the epidermal growth factor receptor (EGFR)-family, angiogenesis, the eicosanoid pathway, the PKC/ Ras/ MAPK pathway, the proteasome and inducers of...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审


    authors: Auberger J,Loeffler-Ragg J,Wurzer W,Hilbe W

    更新日期:2006-06-01 00:00:00